Navigation Links
Echo Therapeutics to Present at Rodman & Renshaw 2009 Annual Global Investment Conference
Date:9/3/2009

FRANKLIN, Mass., Sept. 3 /PRNewswire-FirstCall/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a diabetes management company developing the needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude(TM) SkinPrep System for transdermal drug delivery, announced today that Patrick T. Mooney, M.D., Chairman and Chief Executive Officer, will present at the Rodman & Renshaw 2009 Annual Global Investment Conference on Friday September 11, 2009 at 2:25pm ET. The presentation will occur live and will be held at The New York Palace Hotel in New York, NY.

"We look forward to presenting Symphony, our needle-free, continuous glucose monitoring technology, and Prelude, our needle-free skin preparation technology for transdermal drug delivery, to the large audience of industry leaders, institutional and retail investors from around the world who will be attending the conference. We also plan to provide an update on our notable progress toward our goal of making Symphony and Prelude available to physicians and patients in early 2010," stated Patrick T. Mooney, M.D., Chairman and CEO of Echo Therapeutics.

About Echo Therapeutics

Echo Therapeutics is focused on medical devices and specialty pharmaceuticals. Echo is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units. Echo is also developing its needle-free Prelude SkinPrep System for transdermal drug delivery of a wide range of novel topical reformulations of widely-used, FDA-approved products.

Cautionary Statement Regarding Forward Looking Statements

The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's ongoing studies, including the efficacy of Echo's Symphony tCGM System and Prelude SkinPrep System, the failure of future development and preliminary marketing efforts related to Echo's Symphony tCGM System and Prelude SkinPrep System, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's ability to develop, market and sell diagnostic and transdermal drug delivery products based on its skin ablation platform technologies, including the Symphony tCGM System and Prelude SkinPrep System, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony tCGM System and its Prelude SkinPrep System. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its annual report on Form 10-K for the year ended December 31, 2008, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. Echo Therapeutics, Inc. undertakes no obligation to publicly update or revise any forward-looking statements.

    For More Information:

    Patrick T. Mooney, M.D.
    Chairman and Chief Executive Officer
    (508)-530-0329
    www.echotx.com


'/>"/>
SOURCE Echo Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Cornerstone Therapeutics to Present at Two Upcoming Investor Conferences
2. Selexis and NKT Therapeutics Enter Into Research Services Agreement
3. FDA Accepts to File Cell Therapeutics New Drug Application for Pixantrone
4. Oxygen Biotherapeutics, Inc. to Begin Oxycyte(R) Phase II Clinical Trials in Switzerland
5. Nile Therapeutics Reports 2009 Second Quarter Financial Results
6. Epix Pharmaceuticals, Inc. Announces PRX-07034 Therapeutics - CNS Phase 2 Will be Part of the Intellectual Property Offered for Sale at the September 30, 2009 Auction
7. Plasma Protein Therapeutics Association Urges CMS For Appropriate Hospital Outpatient Drug Reimbursement
8. Prime Therapeutics 2009 Drug Trend Insights Shows Drug Spending Slows to Lowest Rate on Record
9. Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results
10. Rx for Africa, Inc. and Zirus, Inc. Create Joint Venture, ZiRx Therapeutics, Ltd.
11. Transition Therapeutics to Present at Canaccord Adams 29th Annual Global Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... , ... Gout is like no other joint pain. It strikes suddenly, like ... swelling and redness. It is triggered by the crystallization of uric acid within the ... susceptible, according to the February 2016 issue of Harvard Men's Health Watch. , The ...
(Date:2/10/2016)... ... February 10, 2016 , ... For additional information contact Phyllis ... Pioneering book "Better with Age: The Ultimate Guide to Brain Training" by award-winning author ... memory. The book’s publication date is March 16, 2016. A free review copy ...
(Date:2/10/2016)... (PRWEB) , ... February 10, ... ... Florida – 1 UNF Drive, Jacksonville, FL 32224, February 26th: Amateur & ... 27th: Elite Division - Time: 7:00pm – 10:00pm | Ticket Prices $30, ...
(Date:2/10/2016)... ... February 09, 2016 , ... A new leadership team for ... FHU President Joe Wiley made the announcement Monday night, Feb. 8, prior to the ... graduate of FHU and the creator of GO! Camp, has been named director. Gayle ...
(Date:2/10/2016)... ... February 10, 2016 , ... It’s that time of year when most people ... the Interscholastic Athletic Association of Maryland (IAAM), Hall of Fame athlete and Garrison Forest ... cast aside. , That’s why one of her first decisions when her IAAM two-year ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... India , February 10, 2016 ... The "Personalized Medicine, Targeted Therapeutics and Companion Diagnostic ... Trends, Technologies, Participants, and Environment" research report indicates ... worth over $149 billion by 2020 growing at ... up of companion diagnostics and targeted therapeutics and ...
(Date:2/10/2016)... LONDON , February 10, 2016 ... window and M 1 receptor selectivity   ... Heptares StaR® technology, which has entered clinical development ... patients with dementia and schizophrenia.   --> ... StaR® technology, which has entered clinical development as ...
(Date:2/9/2016)... Feb. 9, 2016  Misonix, Inc. (NASDAQ: ... designs, manufactures and markets innovative therapeutic ultrasonic products ... cosmetic surgery, laparoscopic surgery and other surgical applications, ... and the first half of fiscal year 2016 ... --> --> Highlights for the ...
Breaking Medicine Technology: